The Technical Analyst
BioTelemetry Inc [BEAT]
Exchange: NASDAQ Sector: Healthcare Industry: Health Information Services
BioTelemetry Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.95% $2.00
America/New_York / 24 apr 2024 @ 09:33
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 52.66 mill |
| EPS: | -0.720 |
| P/E: | -2.78 |
| Earnings Date: | May 11, 2024 |
| SharesOutstanding: | 26.33 mill |
| Avg Daily Volume: | 0.128 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.78 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -2.78 | industry: PE -4.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.796 (-60.19%) $-1.204 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.820 - 2.18 ( +/- 9.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-09-29 | De Urioste George | Sell | 5 500 | Common Stock |
| 2023-09-27 | De Urioste George | Sell | 1 834 | Common Stock |
| 2023-09-28 | De Urioste George | Sell | 8 000 | Common Stock |
| 2023-09-22 | De Urioste George | Sell | 2 393 | Common Stock |
| 2023-09-26 | De Urioste George | Sell | 5 000 | Common Stock |
| INSIDER POWER |
|---|
| 77.39 |
| Last 95 transactions |
| Buy: 4 127 182 | Sell: 739 646 |
Forecast:
11:12 - $2.08
Live Trading Signals (every 1 min)
Forecast
1: 09:42 - $2.04
Forecast 2: 10:32 - $2.08
Forecast 3: 11:12 - $2.08
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.00 (-1.95% ) |
| Volume | 0.0027 mill |
| Avg. Vol. | 0.128 mill |
| % of Avg. Vol | 2.13 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BEAT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BEAT
HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.
Latest Press Releases
2024-04-09 08:31:00 - Press Release
Heartbeam Presents Positive Results On Its Artificial Intelligence Capabilities For Detecting Arrhythmias
Santa clara, calif.--(business wire)--heartbeam presents positive results on its artificial intelligence capabilities for detecting arrhythmias.
2024-03-20 16:05:00 - Press Release
Heartbeam Reports Fourth Quarter And Full Year 2023 Financial Results
Santa clara, calif.--(business wire)--heartbeam reports fourth quarter and full year 2023 financial results.
2024-03-14 08:31:00 - Press Release
First Patients Enrolled In Pivotal Study Evaluating Heartbeam's Aimigo™ System For Synthesizing A 12-lead Ecg
Santa clara, calif.--(business wire)--first patients enrolled in pivotal study evaluating heartbeam's aimigo™ system for synthesizing a 12-lead ecg.
2024-03-07 08:31:00 - Press Release
Heartbeam Receives Two New Us Patents For Its Core Cardiac Monitoring Technology
Santa clara, calif.--(business wire)--heartbeam receives two new us patents for its core cardiac monitoring technology.
2024-03-05 08:31:00 - Press Release
Heartbeam To Host Fourth Quarter And Full Year 2023 Results Conference Call On Wednesday March 20, 2024 At 4:30 P.m. Eastern Time
Santa clara, calif.--(business wire)--heartbeam to host fourth quarter and full year 2023 results conference call on wednesday march 20, 2024 at 4:30 p.m. eastern time.
Latest News
2024-04-09 08:31:00 - Business Wire
HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias.
2024-03-20 20:53:48 - InvestorPlace
BEAT Stock Earnings: HeartBeam Meets EPS for Q4 2023
HeartBeam (NASDAQ: BEAT ) just reported results for the fourth quarter of 2023. HeartBeam reported earnings per share of -13 cents.
2024-03-20 19:35:23 - Seeking Alpha
HeartBeam, Inc. (BEAT) Q4 2023 Earnings Call Transcript
2024-03-05 08:31:00 - Business Wire
HeartBeam to Host Fourth Quarter and Full Year 2023 Results Conference Call on Wednesday March 20, 2024 at 4:30 p.m. Eastern Time
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Fourth Quarter and Full Year 2023 Results Conference Call on Wednesday March 20, 2024 at 4:30 p.m. Eastern Time.
2023-10-31 08:31:00 - Business Wire
HeartBeam to Host Third Quarter 2023 Results Conference Call on Tuesday November 14, 2023 at 4:30 p.m. Eastern Time
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Third Quarter 2023 Results Conference Call on Tuesday November 14, 2023 at 4:30 p.m. Eastern Time.
2023-08-13 13:03:07 - Seeking Alpha
HeartBeam, Inc. (BEAT) Q2 2023 Earnings Call Transcript
HeartBeam, Inc. (NASDAQ:BEAT ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Branislav Vajdic - Founder & Chief Executive Officer Robert Eno - President Richard Brounstein - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Greetings and welcome to the HeartBeam Second Quarter 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
2023-05-14 05:21:09 - Seeking Alpha
HeartBeam, Inc. (BEAT) Q1 2023 Earnings Call Transcript
HeartBeam, Inc. (NASDAQ:BEAT ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Branislav Vajdic - Founder and Chief Executive Officer Rob Eno - President Richard Brounstein - Chief Financial Officer Conference Call Participants Jason Kolbert - Dawson James William Sutherland - The Benchmark Company Ben Haynor - Alliance Global Partners Operator Greetings and welcome to the HeartBeam First Quarter 2023 Financial Results Conference Call. At this time all participants are in listen only mode.
2023-04-13 08:16:04 - Seeking Alpha
6 Disruptive Stocks That Will Benefit From Interest Rate Policy Change
Early commercial stage companies burn cash as they scale. A rising interest rate environment is a headwind for companies burning cash.
2023-03-17 01:06:05 - Seeking Alpha
HeartBeam, Inc. (BEAT) Q4 2022 Earnings Call Transcript
HeartBeam, Inc. (NASDAQ:BEAT ) Q4 2022 Results Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Branislav Vajdic - Founder and Chief Executive Officer Robert Eno - President Richard Brounstein - Chief Financial Officer Conference Call Participants Jason Kolbert - Dawson James William Sutherland - The Benchmark Company Ben Haynor - Alliance Global Partners Operator Greetings. And welcome to the HeartBeam Fourth Quarter and Full-Year 2022 Financial Results Conference Call.
2022-12-16 14:40:40 - Seeking Alpha
Cash Out Or Hold On To HeartBeam?
I can only give HeartBeam a hold rating. This cardiac technology firm's stock has risen too much recently. BEAT's 3-month price performance is +349.22%. I think investors should take profit now because its product still has no FDA approval. Zero revenue until now.